Dr. Winfried Wunderlich

Assay Development: Development of 2D and 3D "bone marrow niche" drug screening assays with higher predictivity by incorporating the microenvironment followed by high content screening. Drug Discovery and Hit2Lead Development: Hit discovery using a the "niche-based" drug screening assay followed by Hit characterization, Hit expansion, Hit optimization and Hit2Lead development using in vitro efficacy, in vitro toxicity, in vivo pharmacokinetics, in vivo toxicity and in vivo efficacy assays.

Assay Development: Development of a screening assay mimicking "inflammatory adipose tissue" using human primary cells, secretome analysis and high content imaging Exploring zebrafish as a toxicological screening tool Drug Discovery: Hit discovery and hit characterization using a plant extract library Develop Instrumentation Designing and overseeing the engineering of an automated screening analysis platform for automation of cultivation, plate handling and pipetting as well as confocal microscopy.

Phage Display and Yeast-2-Hybrid screening for dominant interaction disruptors of a MEK-MAPKK scaffold Generating combined retroviral contructs for knockdown+inducible rescue of MEK-MAPKKs in prostate cancer and melanoma cell lines Investigative drug characterization (with Pfizer Inc.) in prostate cancer and melanoma cell lines in 2D and 3D cell survival assays as well as orthotopic prostate cancer and melanoma mouse models

TGFbeta signal transduction in early embryogenesis of the chicken, MAPK signal transduction in breast cancer